BOUCHARD LAB
We are dedicated to advancing biology research and sharing our love of science with the broader community.
What we do
Our research interests are radiobiology, tumor microenvironment and metabolism.
Signifiance
Radiotherapy is often the only curative option for patients with inoperable tumors. Our research has the potential to improve patient outcomes by targeting radioresistance, which is one of the primary reasons for radiotherapy failure.
Goals
- To investigate metabolic reprogramming in tumor-stroma interactions through the O-glycoproteome and identify new targets to overcome radioresistance.
​
- To bridge the gap between patient-derived in vitro models and humans pathological samples to understand spatiotemporal dynamics of tumor compartments under treatment and identify resistant spatial patterns.
Tools
Multiplexed immunofluorescence imaging​
​
Patient-derived models
​
Mass spectrometry​
​
Computation
Who we are
About Dr. Gina Bouchard
Dr. Bouchard received her bachelor’s degree in pharmacology and her doctorate in Radiation Science and Biomedical Imaging in the laboratory of Dr. Benoit Paquette at the University of Sherbrooke, Canada. During her thesis, Dr. Bouchard studied the effects of radiation on breast cancer cell migration and invasiveness.
Dr. Bouchard received a postdoctoral fellowship from Stanford University to join the Cancer Systems Biology program with the primary goal of training cancer biologists for bioinformatics, and vice versa. During her postdoctoral research in Dr. Sylvia Plevritis' laboratory, Dr. Bouchard investigated the intercommunication between cancer cells and fibroblasts from various sites of lung adenocarcinomas using a multi-omics approach.
As an Assistant Professor in the Department of Pharmaceutical Sciences at the University of Colorado - Anschutz Medical Campus, Dr. Bouchard's research utilizes 3D patient-derived assembloids to examine metabolic reprogramming in the stroma, employing a spatial biology approach. The primary objective of her research is to identify spatial features associated with metabolic resistance and optimize radiotherapy in cancer patients.
Our Team
JOIN THE TEAM
​
We're always looking to add more enthusiastic scientists to our team, including undergraduate researchers, graduate students, research assistants, data analysts and postdoctoral fellows.
1 / A quantitative spatial cell-cell colocalizations framework enabling comparisons between in vitro assembloids and pathological specimens
​
2025
Bouchard, G., Zhang, W., Ilerten, I. et al. A quantitative spatial cell-cell colocalizations framework enabling comparisons between in vitro assembloids and pathological specimens. Nat Commun 16, 1392 (2025). https://doi.org/10.1038/s41467-024-55129-6
2 / Multiomics Analysis of Spatially Distinct Stromal Cells Reveals Tumor-Induced O-Glycosylation of the CDK4-pRB Axis in Fibroblasts at the Invasive Tumor Edge
​
2022
Bouchard G, Garcia-Marques FJ, Karacosta LG, Zhang W, Bermudez A, Riley NM, Varma S, Mehl LC, Benson JA, Shrager JB, Bertozzi CR, Pitteri SJ, Giaccia AJ, Plevritis SK. Multiomics Analysis of Spatially Distinct Stromal Cells Reveals Tumor-Induced O-Glycosylation of the CDK4-pRB Axis in Fibroblasts at the Invasive Tumor Edge. Cancer Res. 2022 Feb 15;82(4):648-664. doi: 10.1158/0008-5472.CAN-21-1705. PubMed PMID: 34853070; PubMed Central PMCID: PMC9075699.
3 / A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk
​
2020
Gentles AJ, Hui AB, Feng W, Azizi A, Nair RV, Bouchard G, Knowles DA, Yu A, Jeong Y, Bejnood A, Forgó E, Varma S, Xu Y, Kuong A, Nair VS, West R, van de Rijn M, Hoang CD, Diehn M, Plevritis SK. A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk. Genome Biol. 2020 May 7;21(1):107. doi: 10.1186/s13059-020-02019-x. PubMed PMID: 32381040; PubMed Central PMCID: PMC7206807.